|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
4/29/10What's new on Multiple Sclerosis on PubMed
( Posted by-Desinie Smith)
HERVs in Neuropathogenesis. Christensen T. Radiologically isolated syndrome : Multiple sclerosis based solely on MRI findings?] [Article in German] Sellner J, Schirmer L, Hemmer B, Mühlau M. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Johnson KP. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, Loveless S, Robertson NP, Morgan BP. Time-dependent fate of transplanted Neural Precursor Cells in experimental autoimmune encephalomyelitis mice. Angeliki G, Nikolaos G, Eleni P, Athanasios L, Eleni M, Papadopoulos GC. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Buttmann M. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||